{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099328","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.799420+00:00","generated_at":"2026-05-15T16:43:28.220102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027","bullets":["Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.","Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.","Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.","Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.","Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099328","json":"https://secwatch.observer/filing/0001193125-26-099328.json","markdown":"https://secwatch.observer/filing/0001193125-26-099328.md","text":"https://secwatch.observer/filing/0001193125-26-099328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/0001193125-26-099328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/qttb-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:43:28.220102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}